HELP FOR PARENTS

OI General Summary

1. Quick Snapshot

*1	What it means
What it is	A hereditary disorder that weakens bone and connective tissue, making fractures and bone deformities common.
Genes involved	Mutations in COL1A1 or COL1A2 (most common) → abnormal type I collagen. Other genes (e.g., WNT1, SERPINH1, IFITM5) can also cause OI.*1
Inheritance	Autosomal dominant (≈ 85 %) or autosomal recessive (≈ 15 %). *2
Spontaneous	Spontaneous or de Novo is OI that appears within a patient with NO KNOWN OI genetic history. *2
Symptoms	Fractures (often with minimal trauma), bone deformity, short stature, blue/gray sclera, hearing loss, dental issues, joint laxity.
Diagnosis	Clinical (fracture history, physical exam), imaging (X‑ray), genetic testing, biochemical markers (bone turnover).
Treatment	Bisphosphonates, anabolic agents, orthopedic surgery, physical therapy, hearing aids, dental care.
Prognosis	Variable; type I usually mild, types III–IV more severe; advances in medical care have greatly improved life expectancy and quality of life.

NOTES: *1 - There have been recent studies that have demonstrated that issues with WNT1, SERPINH1, HSP 47 and

IFITM, have a place in the study and oncern of patients with OI. Most notably due to the fact that although there has not been found any direct link in patients born with OI, in some infants born with an issue with

WNT1 there is relation to brain development. Again this has not yet been linked to OI patients.

**2 - Currently there is a theory being proposed in major medical studies and publications that the more extreme

cases of OI (V and above) that are often considered very rare here in the US, are showing higher % in other

parts of the world. Additionally the "de NOVO" or spontaneous generation of OI, which is also considered to

be "more rare" here in the US(estimates are 35% < or less), the exact opposite seems true in some other

studies more geographically focused on other countries around the world. To date there has been NO study

that has attempted to correlate the data globally to determine if perhaps thre are environmental issues in

other parts of the planet that contribute to higher percentages of de NOVO, and thus 'more extreme' types.

PERSONAL OBSERVATION - If you find yourself at a cocktail or Christmas party with OI reserchers you may suggest that this would make a great BREAKTHROUGH study.

2. The Biology Behind OI

Component	Normal Role	What Goes Wrong in OI
Type I Collagen	Structural protein giving bone its tensile strength.	Mutations in COL1A1/COL1A2 → defective collagen → weaker bone matrix.
Bone Remodeling	Osteoblasts build bone; osteoclasts resorb bone.	Imbalance can worsen fragility; low bone mineral density.
Other Tissues	Skin, teeth, cartilage, sclera, auditory system	Same collagen defect → blue sclera, dentinogenesis imperfecta, hearing loss.

3. Classification (International Committee for Cranio Facial Pathology – 2016)

Type	Severity	Key Clinical Features
I	Mild	Recurrent fractures, minimal deformity, normal stature	Heterozygous COL1A1 or COL1A2 null alleles
II	Perinatal lethal	Severe bone deformity, respiratory insufficiency	Homozygous or compound heterozygous COL1A1/COL1A2
III	Severe	Progressive bone fragility, short stature, marked deformity	Heterozygous mutations affecting collagen folding
IV	Moderate	Variable fragility, short stature, mild to moderate deformity	Heterozygous missense mutations
V	Variable	Bone fragility + hyperplastic callus, blue sclera, hearing loss	IFITM5 mutation
VI	Rare	Bone fragility + dental abnormalities, short stature	SERPINH1 mutation
VII	Rare	Bone fragility + hyperlaxity, hearing loss	WNT1 or other signaling pathway mutations

Additional sub-types (e.g., type IX, X) have been identified, but the above table covers the most clinically relevant categories. Recently the OIF in America has suggested that the type list be limited to a smaller subset (for example I – VII) and then list the mutations as subsets of those 7. For example (FICTITIOUS EXAMPLE) Previously Type XVIII may have been listed as “Similar to type VI, but with these minor differences. A.B.C,,,,Today it might be listed as TIV,subtype3. Or something like that

4. Clinical Presentation – “What the Patient Might Say”

Spontaneous Symptom	Typical Age of Onset	What to Look For
Fractures	Birth → early childhood	Pathologic fractures after minimal trauma; healed fractures that look “curled”
Blue sclera	Often obvious in infancy	Pale blue or grayish eye whites
Short stature	Childhood	Height below 3rd percentile
Dental issues	Early childhood	Dentinogenesis imperfecta (opalescent teeth, sensitivity, early decay)
Hearing loss	Childhood‑adolescence	Conductive or sensorineural, usually due to stapes fixation or inner ear bone changes
Joint laxity / hypermobility	Childhood	Easy dislocations, frequent sprains
Respiratory problems	Variable	Reduced chest wall compliance, scoliosis, risk of pneumonia
Delayed motor milestones	Infancy → toddler	Due to frequent fractures or bone pain

5. Diagnosis Workflow

Path	Detail
History & Physical	Number and pattern of fractures, family history, growth chart, ocular findings, hearing tests, dental exam.
2. Imaging	X ray of long bones and spine; bone density scan (DXA) if possible. Repeated on a regular basis.
3. Laboratory	Serum calcium, phosphate, alkaline phosphatase, vitamin D. Bone turnover markers (e.g., P1NP, CTX).
4. Genetic Testing	Targeted sequencing of COL1A1/COL1A2 first. If negative, broaden panel to include WNT1, IFITM5, SERPINH1, others. Confirmatory test (Sanger sequencing or MLPA) for large deletions/duplications. MAKE THESE RESULTS Available to caretakers, schools etc
5. Special Tests	Ophthalmologic exam for blue sclera. Audiology testing. Dental panoramic X ray.

6. Treatment Landscape

• Hearing aids; cochlear implants for severe loss

Current Options

Title

Reduce Fractures / Increase Bone Strength

• Bisphosphonates (pamidronate, zoledronic acid) – IV monthly/quarterly
• Denosumab (anti RANKL) – subcutaneous every 6 months (off label in children)
• Anabolic agents (teriparatide) – limited data in children

Supportive Orthopedics

• Intramedullary rodding for long bone fractures
• Spinal surgery for severe kyphosis or scoliosis

Hearing

• Hearing aids; cochlear implants for severe loss

Dental

• Amalgam fillings, crowns, fluoride treatments

Physical & Occupational Therapy

• Strengthening, balance, mobility training

Psychosocial

• Counseling, support groups, school accommodations

Medication Highlights

DRUG

MECHANISM

Typical Pediatric Dosing

NOTES

Pamidronate

Inhibits osteoclast-mediated bone resorption

1–2 mg/kg IV every

3–6 months

Can improve BMD;

monitor for

hypocalcemia

Zoledronic acid

Potent bisphosphonate

0.05 mg/kg IV annually

Faster BMD gains; risk of acute phase reaction

Denosumab

RANKL inhibitor

0.8 mg/kg SC every 6 months

Off label in children; requires monitoring for rebound osteoporosis

Teriparatide

Recombinant PTH (1–34)

20 µg/day SC (FDA approved only in adults)

Not approved in kids;

case reports suggest

benefit, but needs

further study.

7. Prognosis & Life Expectancy

Life Expectancy

Key Factors Influencing Outcomes

I

> 90 % live into adulthood

Fracture management, physical activity level

II

Early life mortality (most die in utero or within first year)

Severity of bone deformity, respiratory support

III

Variable (20–70 yr in modern era)

Recurrent fractures, orthopedic complications, cardiac/respiratory issues

IV

> 80 % live into adulthood

Bone density, treatment adherence

Qvis

V–VII

Variable

Often associated with extra osseous features (e.g., hearing loss)

Note: Modern medical care (bisphosphonates, surgical techniques, pulmonary support) has significantly improved outcomes, especially for severe types.

8. Living with OI – Practical Tips

DOMAIN

ADVICE

Mobility

Use low impact activities (walking, swimming); avoid high impact sports; use supportive footwear; consider wheelchairs or mobility aids for severe cases.

Home & Work

Soft cushioned surfaces; padded furniture; grab bars in bathroom; ergonomic tools; workplace accommodations (flexible schedule, ergonomics).

Nutrition

Adequate calcium & vitamin D; balanced protein; consider supplements if labs low.

Dental Care

Daily fluoride toothpaste, regular check ups, sealants, dental crowns; avoid trauma to teeth.

Mental Health

Peer support groups, counseling, psychoeducation; involve patient in decision making. Recent patient surveys suggest that over 99% of OI patients have been disgnosed as clinically depressed at least one time, or more, in their life. There are also extreme cases that have been classified as PTSD.

Pain Management

Previous studies indicated that only OI patients with high fracture counts may be considered for pain management, recently however the discovery of neuropathic pain and other “unseen” pain centers have begun to sway that thought, tied in with Mental Healthcare.

School

Individual Education Plan (IEP) or 504 Plan; adaptive seating; extended breaks.

Travel

Inform airline staff about OI; request wheelchair assistance; pack medical supplies.

9. Research & Future Directions

Gene Therapy

Viral vectors delivering normal COL1A1/COL1A2 to bone cells; early animal models show promise.

CRISPR/Cas9

Correcting point mutations in vitro; challenges remain for efficient delivery to bone tissue.

Biologic Modulators

Targeting WNT signaling (e.g., romosozumab) may enhance bone formation.

Biomaterials

3 D printed, bio active scaffolds for bone repair.

Patient Reported Outcomes

Developing robust PRO measures specific to OI to guide clinical trials.

10. Key Resources

Resource

What It Offers

International Osteogenesis Imperfecta Foundation (IOIF)

Patient support, news, clinical trials database

NIH OI Registry

Clinical data, research collaborations

Genetic Testing Centers

e.g., Johns Hopkins OI Center, Mayo Clinic

ClinicalTrials.gov

Search for “osteogenesis imperfecta” to find ongoing

studies

TheOIGuy.com LLC

New and Old information, science and medical tests,
procedures, all translated into LAY English

American Academy of Pediatrics (AAP)

Guidelines for pediatric management of OI

Bottom Line

Osteogenesis imperfecta is a spectrum of inherited collagen related disorders that make the skeleton fragile and lead to fractures, deformities, and a host of extra osseous problems. With advances in genetics, bisphosphonate therapy, and orthopedic care, many people with OI now enjoy longer, more active lives. Early diagnosis, multidisciplinary care, and patient centred treatment planning are the cornerstones of successful management. If you or a loved one has concerns about OI, consider reaching out to a specialized bone disease center or a genetics clinic for a personalized evaluation.